Kane Biotech (TSX-V:KNE, OTCQB:KNBIF) CEO Mark Ahrens-Townsend tells Proactive Investors that the technology company, engaged in the development and commercialization of products that prevent and remove microbial biofilms, is looking to expand into Europe, and potentially further.
Ahrens-Townsend says the company licensed two of their technologies to U.K.-based company Dechra Pharmaceuticals for distribution in the North American veterinary channel, saying Dechra could transport them into the European market.
Meet Carnarvon Petroleum Ltd, Southern Gold, Paradigm Biopharmaceuticals Ltd, Petsec Energy Ltd and OncoSil Medical Ltd at our event,Melbourne, 10 April 2018.Register here >>